Literature DB >> 12605128

Orthotopic liver transplantation for hereditary fibrinogen amyloidosis.

S Zeldenrust1, M Gertz, T Uemichi, J Björnsson, R Wiesner, T Schwab, M Benson.   

Abstract

Systemic amyloidosis results from the deposition of insoluble protein fibrils in various organs and tissues. To date, several different proteins have been associated with amyloid fibril formation, including immunoglobulin light chain, serum amyloid A protein, and transthyretin. Recent reports have shown that variant fibrinogen chains can form amyloid in certain kindreds. Hepatic transplantation has previously been reported in the treatment of hereditary amyloidosis associated with variant transthyretin proteins, which are mainly synthesized in the liver. This article reports the first use and long-term follow-up of combined hepatic and renal transplantation in the successful treatment of two patients with hereditary fibrinogen amyloidosis. Both patients experienced sustained improvement in renal function and nutritional status at 61/2 years and 28 months of follow-up, respectively. Orthotopic liver transplantation is effective and potentially curative treatment of hereditary fibrinogen amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605128     DOI: 10.1097/01.TP.0000046526.10003.EC

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Cardiol       Date:  2007-08       Impact factor: 2.882

Review 2.  Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.

Authors:  Walid Hassan; Hani Al-Sergani; Walid Mourad; Rashed Tabbaa
Journal:  Tex Heart Inst J       Date:  2005

3.  Current treatment in cardiac amyloidosis.

Authors:  Ivana Kholová; Josef Kautzner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

4.  Three German fibrinogen Aalpha-chain amyloidosis patients with the p.Glu526Val mutation.

Authors:  Magdalena Eriksson; Stefan Schönland; Raoul Bergner; Ute Hegenbart; Peter Lohse; Hartmut Schmidt; Christoph Röcken
Journal:  Virchows Arch       Date:  2008-05-24       Impact factor: 4.064

5.  An unusual case of cardiac amyloidosis.

Authors:  Brian Garibaldi; David Zaas
Journal:  J Gen Intern Med       Date:  2007-04-20       Impact factor: 5.128

Review 6.  Amyloid nephropathy.

Authors:  Mazdak A Khalighi; W Dean Wallace; Miguel F Palma-Diaz
Journal:  Clin Kidney J       Date:  2014-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.